Physician profile
Hanning You
NPI 1124555404
$1,513.56
in general payments reported to CMS, 2019-2025
14 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $192 · 2023: $472 · 2024: $588 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $250.03 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $245.61 | 2023-2024 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.76 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $168.08 | 2023-2025 | |
| Ardelyx, INC. | $151.13 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Glaxosmithkline, LLC. | $136.29 | 2023 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $124.00 | 2023 | Jynarque |
| Vifor Pharma, INC. | $94.98 | 2022-2024 | Veltassa |
| Lilly USA, LLC | $43.38 | 2023-2025 | Jardiance, Zepbound |
| Calliditas Therapeutics US INC. | $30.25 | 2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $23.18 | 2023 | Ultomiris |
| Amgen INC. | $20.94 | 2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $20.67 | 2024 | Lokelma |
| Scpharmaceuticals INC. | $18.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanning You listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.